Eligard and Bone Loss
Healthcare providers often recommend Eligard® (leuprolide acetate) to treat advanced prostate cancer. This medication comes in injectable form and is administered via subcutaneous injection every one, three, four, or six months, depending on various factors.
Eligard may decrease bone density, which could lead to bone loss and increase your risk for osteoporosis and fractures. People who already have osteoporosis, or who have risk factors for this condition, such as people who regularly use alcohol or tobacco or who have a family history of osteoporosis, may be at greater risk.
(To learn more about the risk of bone loss with this medication, click Eligard Warnings and Precautions. This article also provides other important safety considerations to keep in mind during treatment.)